Research snapshot · Not reviewed

TXG10x Genomics

Single-cell and spatial biology platform

Open TXG in Robinhood ↗
WATCH
Conviction●○○○○1 of 5
Research targetSnapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap4.95BSnapshot value

Single-cell + spatial biology platform leader. 10x Chromium is the dominant single-cell platform; Visium/Xenium/Atera for spatial. 15% CAGR spatial biology market driven by oncology.

Atera platform launch (Q1 2026) expanding spatial capabilities; Roche Axelios single-cell/spatial partnership; rising cancer burden (35M+ new cases projected by 2050) driving spatial adoption.

Pre-revenue trajectory — unprofitable, narrative-driven; FFPE compatibility and cost remain adoption limiters; competitive pressure from Bruker/Vizgen/Akoya; single-cell market maturation.

needs X/Reddit sentiment sweep

Snapshot · Not reviewed

🟡 Mixed · ins-$3.4M · 13F 15+/9- · short↑0.28

Snapshot · Not reviewed